Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interesting and promising article: "Vaccination, Paxlovid decrease risk of long Covid, studies show"
It would be even more encouraging to see data indicating that Tollovid has the same impact.
https://www.cnn.com/2023/03/23/health/long-covid-vaccination-paxlovid/index.html
Thanks for posting. Disturbing content.
Toxic debt financing has always been the Achilles heel for Todos and Amarantus. Having said that, I still have confidence in the products and services of these micro-cap companies. Obtaining adequate financing for small cap companies is a universal challenge and the problem is especially acute now.
New SC 13D filed on Edgar. This explains the recent issuance of so many shares of Todos. It represents partial payment of the debt incurred as a result of purchasing Provista.
See: https://www.sec.gov/Archives/edgar/data/1645260/000149315223005394/formsc13d.htm
Item 3. Source and Amount of Funds or Other Consideration
The 151,404,000 shares of the Company were issued to SIH as payment for $1,097,000 of a $3,500,000 Convertible Note issued by the Company as partial payment for the Company’s purchase of Provista Diagnostics, Inc from SIH.
Excellent segment on PBS News Hour tonight regarding Long Covid. Sixty-five million people worldwide are suffering from Long Covid. Hopefully, this coverage will be helpful in emphasizing the magnitude of this challenge.
Piece from NY Times amplifies concerns in previous post:
https://www.nytimes.com/2023/02/03/opinion/bird-flu-h5n1-pandemic.html?unlocked_article_code=S9FtF0DV4CQx6mhD4VY_pfqjzKiAv19wfgiv9Q2teUw1qjgTlJR7KOf9OTP-rPtxQ3wV8Xn8MD-VjpgXYR9n4394VoZFEcYavrQaKMlksjOkzq_Xsc-KzQJoJLRaD29GmhFXNsjB8WpSQm05hKbGRTXPAMu1Z1e3nvvmK3el_OwT2BR9VW90-mrOQc0b9TaqPPFpr2gHXK_fuwDKrKaUnySScNirOZoRqMTVaezAahe1CK-oVqmQs2jpy4pBmRvfw5-VNZmKS1QiwdDBBDeNkqOtC-l4iU_8izdtzi5Vr0ssczBK5nhRD-nlXOxDBsKsPa5GweIXrEiXfUg-cV1jKQ&smid=share-url
Interesting Tweet from GC:
200M that we know of… let’s be honest, next pandemic already here. Seeded in animals will explode to humans, and for the everyone who isn’t thinking about recombinations amid sentient wide weakened immune systems cross spread is sinking head in sand. We are working on it already https://t.co/4G0nrtCcTI
— Gerald Commissiong (@G_Commish) February 4, 2023
This could be the catalyst that Todos needed for many other actions to fall into place.
All 44 pages of the Patent in the PDF below:
https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11564587
Concur;
From Justia regarding Dorit Arad patent just granted:
Physical methods for living tissue inactivation and detection, and physical methods in use for the detection and inactivation of living bodies (like Ebola and 2019 Coronavirus) in living systems and non-living systems thereof
Patent number: 11564587
Abstract: A system for detecting presence of coronavirus in a subject, the system including a first pad for placing a first hand, the pad including a contact to measure conductance of the subject's body, a conductance meter connected to the contact, a second pad for placing a second hand, a source of electromagnetic radiation for irradiating the second pad. A system for detecting presence of coronavirus in a subject, the system including a chip with a plurality of wires disposed on or in the chip, a conductance meter arranged to measure conductance between the wires, and biological material associated with the coronavirus disposed on or in the chip. Related apparatus and methods are also described.
Type: Grant
Filed: August 18, 2021
Date of Patent: January 31, 2023
Inventor: Dorit Arad
Pfizer's stellar earnings report is out along with guidance for this year. Although overall demand for Covid related products is expected to decline significantly, the price for those products will rise once government subsidies stop later this year. Implications for Todos and Covid/long-Covid initiatives seem to point to a mixed bag.
https://www.cnbc.com/2023/01/31/the-covid-pandemic-drives-pfizers-2022-revenue-to-a-record-100-billion.html
Good synopsis from NY Times on Covid policy changes in the works:
https://www.nytimes.com/2023/01/30/us/politics/biden-covid-public-health-emergency.html?unlocked_article_code=8IUv3_uU9N44B8zBZqOuigFZ8OuutOZVj2or_QxHnVAJXSHPI_BhSWcoBGE1v-npBRLSndVQ7hcBdLls09uKidLnHJXUS6GiYSp_mp2NNXRtrQLxfomjUPaFfmeMoqkVXSnkg9rlS4SXt4-1Z1CVSDwHEftccgfiuLVbvYD-0qNmip1XtceWAnnVA4_zCFczugzRbhArqUpN6POdIAoVpBgIAW7jryHkmNkoC3bh0_tlTkbZn6byRWO3hows9VE-nWnZugqVOw3C-wR9OyaPRJj3MxzIcrtszZu6mlA25_NWwFOQNRI-_nCK7-63mwvir7b4evt5UbGx4KFetWOg5h8a_S_QVFuSOEU__O4ZALyY&smid=share-url
It will be interesting to see if any "major" business publication picks up on this report. Todos may possess a wealth of knowledge about 3CL Protease inhibition but to refer to it as a "Major Giant" along with Pfizer was a red flag to me. Todos is a small business. How much is known about Coherent Business Insights/Stratagem Market Insights? They show the same office address in Burlingame, CA and are headquartered in India. A bit of caution may be warranted.
I appreciate your rationale for the lack of news. My view is that we are due an update because of the milestones that were anticipated to be met in December and early January. We had seven press releases in November. The last PR was December 6. The lack of updates may have also contributed to the steady decline in stock price. We have had a persistent downward trajectory for two years and significant dilution. I'd like to do some dollar cost averaging but I need some assurance that strategic milestones are being met.
The two videos below provide a good refresher on the current focus of Todos. An update video would be appreciated by investors.
Please check your link to "Top Secret Todos DD."
Thanks for that feedback. I too wanted to take advantage of the end of year sale but did not want to use PayPal or Venmo even though I have those accounts. I was corresponding with the company over the issue but then was out of the country for a couple weeks and was unable to follow up until this week. Customer service at mytollovid.com was receptive to my concerns and I was advised earlier this week to purchase two bottles of Tollovid from Amazon and they would forward me a free bottle. I just had to provide my Amazon order numbers to them. I appreciate their willingness to work with me. Hopefully there will be another sale soon for those who need to stock up.
During the past couple of weeks I've corresponded with Todos regarding the payment options for Tollovid on mytollovid.com. For some time now the only payment options were either PayPal or Venmo. I was concerned that Todos might be losing potential customers who wanted to use mytollovid.com but did not like using these options and preferred using major credit cards. I received notice today that the major credit card companies are now accepted on mytollovid.com. I just confirmed that this action had been taken.
And yet on the mytollovid.com website the whole panoply of credit cards is listed as available to pay for the product.
I tried to place an order as I have in the past using my Discover card, but couldn't. In my "chat" I received the following response: "Our credit card system is currently down. As such, the only payment option is PayPal. We apologize for any inconvenience this may cause."
Just saw this today...good time to restock.
New Year, New Life With Tollovid! Stock Up Now With Our End of Year Sale! Buy 3 Bottles for $299#COVID19 #tollovid #treatlongcovid #immunesupport #supplementsthatwork pic.twitter.com/qBe4ep7HT1
— mytollovid (@mytollovid) December 29, 2022
In the "for what it's worth category" I did an inquiry to see if the newly leased facility in Cleburne, Texas might fall into a Small Business Administration HUB Zone, and it does. Historically Underutilized Business (HUB) Zones can provide a significant competitive advantage for companies competing for government contracts. Of course there are many caveats for companies wishing to qualify for the program.
https://maps.certify.sba.gov/hubzone/map#center=32.384963,-97.389843&zoom=15&latlng=32.384962,-97.389794
From NY Times: ‘Tragic Battle’: On the Front Lines of China’s Covid Crisis
https://www.nytimes.com/2022/12/27/world/asia/china-covid-hospital-crisis.html?unlocked_article_code=hJrauS4OH68PvoCGxhE_P1hgM0tzze2XkADPUqi0o9g0VZs8mt8ODtm_TMcPcv8OCmCpmCn8PU83RBDDgyMw-jpAUfgM5pdQVXe1Fq-tzjRop9zMAvfgMHH0NVs2YlYR3Z6n89PJFCfX97IHOws-GibP_SIpQ98YeR58NDOBlFFVZs-GXaH2df-6bVeDKF6SJk1gvcHgA16kU0RS0cifGyTTG5tYS11Ob8me-hU-CR1_I_Dh-Kz1vjEvZolYHJHasLalQolXvzZ5n-0peoS7wF5w8_sVWC03jW4e50ZBUMZksI7-D_0N2vv2XWU3Ry9zWTeLEZvxp7Z04Amifrq0uhoPEfmMO71-&smid=share-url
Status of inquiries about Tollovid from China?
Interesting article from Fortune and potential testing market for Todos/3CL Pharma:
"COVID isn’t just infecting you—it could be reactivating viruses that have been dormant in your body for years"
https://fortune.com/well/2022/12/26/is-long-covid-chronic-fatigue-syndrome-myalgic-encephalomyelitis/
Interactive link to new ad for Tollovid: https://mytollovid.com/
New ad for Tollovid on GC's Twitter response::
— Gerald Commissiong (@G_Commish) December 23, 2022
"Covid-19 and overdose deaths drive U.S. life expectancy to a 25-year low"
Several news services have written on the drop in life expectancy in the US today. The Politico article below is representative. With significant acceptance of Tollovid by the public, Todos/3CL Pharma could help contribute to the reversal of this devastating negative trend.
https://www.politico.com/news/2022/12/22/covid-19-and-overdose-deaths-drive-u-s-life-expectancy-to-a-25-year-low-00075081
I appreciate your point of view but in this case I must disagree. I feel some form of rebuttal is necessary.
My goal in posting the "NASA researcher's" exceptionally negative post was to point out that Todos has an opportunity to rebut, refute, or otherwise discredit the claims he presented. Todos has not taken that opportunity so the review remains on Amazon...unchallenged...and 44 potential customers found the post to be helpful.
See post 14204.
With a population of 1.412 billion people I could imagine a need for "millions" of bottles.
Ominous reports from China below and China's recent interest in Tollovid...could there be linkage?
From Reuters: "Hearses queue at Beijing crematorium, even as China reports no new COVID deaths"
https://www.reuters.com/world/china/beijing-braces-surge-severe-covid-cases-world-watches-with-concern-2022-12-21/
"The abrupt change of policy has caught a fragile health system unprepared and hospitals are scrambling for beds and blood, pharmacies for drugs, and authorities are racing to build special clinics. Experts predict China could face more than a million COVID deaths next year."
Noted!
Latest from Wefunder on 3clpharma:
https://wefunder.com/3clpharma
I agree with you about mimicking the dosage taken by Dr. Arad and GC . I believe Dr. Arad said six pills per day before an event...which is what I also do. Congratulations on avoiding Covid for the last two years; however, you might want to reconsider a booster.
My only concern about the dosing recommended is that it doesn't address those of us who have been taking Tollovid (one or two pills per day) for about two years to keep our immune systems boosted. One could argue that we should seek guidance from our doctors...who in most cases know nothing about Tollovid.
I like the look of the new labels.
Thanks for your comments about Amazon reviews. I appreciate your views and although you don't put much weight on Amazon reviews, many people do, including myself. An overall rating of 3.7 causes one to look more closely at the lowest ratings to see what people are most concerned about. In many cases one can rule out the low ratings because of clearly disgruntled customers who provide no substance to their complaint. Other reviews, like the one I posted, cause more concern (44 people found the review to be helpful) and should be addressed by the supplier.
I never saw the deleted message, but my point in showing that particular review was that Todos had not taken the opportunity to present a rebuttal or explanation of any kind. Many companies will post comments on Amazon relative to especially egregious reviews that can often sway the opinion of the potential customer. It is my opinion that all reviews that are rated 1 or 2 and maybe even 3 should have some comment from marketing. To let this review remain as it is represents an unforced error.
This is an example of an negative Amazon review that Todos needs to address. This one review could have discouraged many potential buyers of the product. Action required by Todos/3CL Pharma.
NASAGUY
1.0 out of 5 stars Former NASA researcher sees a problem here
Reviewed in the United States ???? on October 11, 2022
Verified Purchase
Training at NASA you learn to understand real science, meaning that there can be tremendous value to case studies. I always say "Did the heart not exist before the EKG?". BUT, when Tollovid as a company makes claims about scientific research where they use the name of a Dr. Lee Morgantaler (sp?) as the doctor, but when you actually go to the researchgate website and find out the first author FIRST is actually a VP at the company? The medical world now rejects all research funded by pharmaceutical companies, yet this is clearly the case with Tollovid. It would be fine if this guy had some scientific background (there is no degrees cited on Linkedin), but it is disturbing to see him as first author (this means he most likely wrote the entire paper and just got a DO to put his name on it. You don't even know if the DO was paid, as the Researchgate paper is not even published. It is only an abstract. But the way it is presented on the website, it is clearly making it appear that major research has gone into this product.
My personal experience? It had no impact on any of my symptoms. This does not mean it does not work for others. It may. I just hate when I dig in deep and am so disappointed to see that they overpromise and underdeliver with these research claims. It just then looks like a "marketing" deal rather than a product that is truly designed to help people. It even looks like they are going public and trying to boost their stock value? Not clear.
The other concern? They present the ingredients on the Amazon site, but on the bottle it only says "Proprietary blend". This is always a red flag for me. Why? What if one of the ingredients interacts with a medication I am on? Without the full disclosure of what is in the product, you do not know if it is harmful to you. Individual differences are the norm, meaning something in it may help one person but hurt another. Without knowing the ingredients, how can we tell?
Proceed with caution. When they use the word "research," yet nothing is actually published, AND the author of the publication is an owner in the company, well, it destroys the reputation of the product long-term. I don't mean this to trash them, but just pointing out that their claims of research are very misleading and a disappointment to one trained in doing more than "data skimming." Caveat Emptor.
Read less
44 people found this helpful